Enveric Biosciences (NASDAQ: ENVB) CEO David Johnson and MagicMed CEO Dr. Joseph Tucker joined Steve Darling from Proactive to share news, that Enveric has entered into a definitive agreement to acquire the privately held MagicMed in an all-stock transaction.
Johnson shares with Proactive why they targeted MagicMed and how this deal helps the company in their search of treatments for cancer-related Post Traumatic Stress Disorder.
Tucker shares with Proactive why he thought Enveric was a great partner moving forward and the fact, after the close he will become the combined company’s CEO.